Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Glioma - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 200+ companies and 220+ drugs in Glioma Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Glioma Competitive Landscape
The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Glioma Report Assessment
- Company Analysis
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
- How many companies are developing Glioma drugs?
- How many Glioma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Glioma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glioma and their status?
- What are the key designations that have been granted to the emerging and approved drugs?
Key Players
- Denovo Biopharma
- AstraZeneca
- Pfizer
- Chimerix
- Bristol-Myers Squibb
- Orbus Therapeutics
- Northwest Biotherapeutics
- Day One Biopharmaceuticals
- AiVita Biomedical
- Ascletis Pharma Inc
- Kazia Therapeutics
- HebaBiz Biotech
- Biohaven Pharmaceuticals
- Vigeo Therapeutics
- Hoffman-La-Roche
- TVAX Biomedical
- Laminar Pharmaceuticals
- Kintara Therapeutics
- Medicenna Therapeutics
- Symphogen A/S
- MimiVax
- Incyte Corporation
- Istari Oncology
- Immunomic Therapeutics
- Sanofi
- Merck Sharp & Dohme LLC
- Oblato, Inc.
- GlaxoSmithKline
- NuvOx Pharma
- Epitopoietic Research Corporation
- AnHeart Therapeutics
- DNAtrix
- Arog Pharmaceuticals
- CANbridge Pharmaceuticals
- Jiangsu Hengrui Medicine
- BPGbio, Inc.
- BioMimetix
- CNS Pharmaceuticals
- Ever Supreme Bio Technology
- Chia Tai Tianqing Pharmaceutical Group
- CytoVac
Key Products
- Enzastaurin
- Selumetinib
- Tofacitinib
- ONC201
- Opdivo
- Eflornithine
- DCVax-L
- DAY101
- AV-GBM-1
- ASC40
- Paxalisib
- JP001
- Troriluzole
- VT1021
- Vemurafenib
- TVI-Brain-1
- LAM561
- VAL-083
- MDNA55
- Sym004
- SurVaxM
- Retifanlimab
- PVSRIPO
- LAMP-pp65-DC
- Plerixafor
- Pembrolizumab
- OKN-007
- Niraparib
- NanO2
- ERC1671
- AB-218
- DNX-2401
- Crenolanib
- CAN008
- Camrelizumab
- BPM 31510
- BMX-001
- Berubicin
- ADCV01
- Anlotinib
- ALECSAT
For more information about this report visit https://www.researchandmarkets.com/r/yfta9j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
